Weather Conditions May Affect Prostate Cancer Patients.
A unique swotting links dry, cold weather to higher rates of prostate cancer. While the findings don't corroborate a direct link, researchers suspect that weather may affect adulteration and, in turn, boost prostate cancer rates. "We found that colder weather, and downcast rainfall, were strongly correlated with prostate cancer," researcher Sophie St-Hilaire, of Idaho State University, said in a scuttlebutt release.
So "Although we can't say exactly why this correlation exists, the trends are constant with what we would expect given the effects of climate on the deposition, absorption, and degradation of persistent systematic pollutants including pesticides". St-Hilaire and colleagues studied prostate cancer rates in counties in the United States and looked for links to state weather patterns.
They found a link, and suggest it may exist because polar weather slows the degradation of pollutants. Prostate cancer will strike about one in six men, according to CV information in the study. Reports suggest it's more common in the northern hemisphere.
Showing posts with label prostate. Show all posts
Showing posts with label prostate. Show all posts
Monday 17 February 2020
Wednesday 22 January 2020
Smoking And Weight Gain Increases The Death Rate From Prostate Cancer
Smoking And Weight Gain Increases The Death Rate From Prostate Cancer.
Men treated for prostate cancer who smoke or put on glut pounds amass their discrepancy of disease recurrence and of dying from the illness, two new studies show. The findings were presented Tuesday at the American Association for Cancer Research's annual conclave in Washington, DC.
In the fundamental report, a team led by Dr Jing Ma, an associate professor of pharmaceutical at Brigham and Women's Hospital in Boston, found that obesity and smoking may not be risk factors for developing prostate cancer, but they do augmentation the odds that a man who has the illness will die from it. Being overcast and smoking "predispose men to a significantly high risk of cancer-specific and all-cause mortality," Ma said during a Tuesday matinal news conference.
"Compared to lean non-smokers, obese smokers had the highest jeopardy of prostate cancer mortality". For the study, Ma's team collected data on more than 2700 men with prostate cancer who took role in the Physicians Health Study. Over 27 years of follow-up, 882 of the men died, 11 percent from the cancer.
The researchers found that both avoirdupois move further and smoking boosted the risk for dying from the cancer. In fact, every five-point flourish in body mass index (BMI) increased the risk for dying from prostate cancer by 52 percent. BMI is a assessment of height versus weight, with the threshold of overweight set at a BMI of 25 and the sill for obesity set at a BMI of 30.
In addition, men who smoked increased their risk for dying from the cancer by 55 percent, compared with men who never smoked, the muse about found. "These data underscore the lack for implementing effective preventive strategies for weight control and reducing tobacco use in both fit men as well as prostate cancer patients".
In a second report, a team led by Corinne E Joshu, a postdoctoral colleague in the department of epidemiology at Johns Hopkins Bloomberg School of Public Health, found that men who gained preponderance after having their prostate removed were almost twice as likely to discover their cancer return as were men who maintained their weight. "Weight gain may increase the risk of prostate cancer recurrence after prostatectomy," Joshu said during the AACR advice conference.
"Obesity, especially among serene men, may also contribute to the risk of prostate cancer recurrence". For the study, Joshu's crew collected data on more than 1300 men with localized prostate cancer who underwent prostatectomy between 1993 and 2006. In addition, the men completed a examine on diet, lifestyle and other factors such as weight, zenith and physical activity five years before surgery and again one year after the procedure.
Men treated for prostate cancer who smoke or put on glut pounds amass their discrepancy of disease recurrence and of dying from the illness, two new studies show. The findings were presented Tuesday at the American Association for Cancer Research's annual conclave in Washington, DC.
In the fundamental report, a team led by Dr Jing Ma, an associate professor of pharmaceutical at Brigham and Women's Hospital in Boston, found that obesity and smoking may not be risk factors for developing prostate cancer, but they do augmentation the odds that a man who has the illness will die from it. Being overcast and smoking "predispose men to a significantly high risk of cancer-specific and all-cause mortality," Ma said during a Tuesday matinal news conference.
"Compared to lean non-smokers, obese smokers had the highest jeopardy of prostate cancer mortality". For the study, Ma's team collected data on more than 2700 men with prostate cancer who took role in the Physicians Health Study. Over 27 years of follow-up, 882 of the men died, 11 percent from the cancer.
The researchers found that both avoirdupois move further and smoking boosted the risk for dying from the cancer. In fact, every five-point flourish in body mass index (BMI) increased the risk for dying from prostate cancer by 52 percent. BMI is a assessment of height versus weight, with the threshold of overweight set at a BMI of 25 and the sill for obesity set at a BMI of 30.
In addition, men who smoked increased their risk for dying from the cancer by 55 percent, compared with men who never smoked, the muse about found. "These data underscore the lack for implementing effective preventive strategies for weight control and reducing tobacco use in both fit men as well as prostate cancer patients".
In a second report, a team led by Corinne E Joshu, a postdoctoral colleague in the department of epidemiology at Johns Hopkins Bloomberg School of Public Health, found that men who gained preponderance after having their prostate removed were almost twice as likely to discover their cancer return as were men who maintained their weight. "Weight gain may increase the risk of prostate cancer recurrence after prostatectomy," Joshu said during the AACR advice conference.
"Obesity, especially among serene men, may also contribute to the risk of prostate cancer recurrence". For the study, Joshu's crew collected data on more than 1300 men with localized prostate cancer who underwent prostatectomy between 1993 and 2006. In addition, the men completed a examine on diet, lifestyle and other factors such as weight, zenith and physical activity five years before surgery and again one year after the procedure.
Monday 23 December 2019
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved restorative prostate cancer vaccine, Provenge, is conservative and has few airs effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both cover and clinical data," said prima donna researcher Dr Simon J Hall, bench of urology at Mount Sinai Medical Center in New York City.
This refuge data shows that there are very limited side effects. The superiority of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer side stuff than chemotherapy, which is the only other treatment option for these patients. In addition, Provenge has improved survival over chemotherapy.
The mean survival time for men given Provenge is 4,5 months, although some patients saw their lives extended by two to three years. "This is a newly nearby treatment, with very limited standpoint effects, compared to anything else that a man would be considering in this state". Hall was to present the results on Monday at the American Urological Association annual convergence in San Francisco.
Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved nobility of viability and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do appear as activities without any restrictions, the researchers noted.
The newly approved restorative prostate cancer vaccine, Provenge, is conservative and has few airs effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both cover and clinical data," said prima donna researcher Dr Simon J Hall, bench of urology at Mount Sinai Medical Center in New York City.
This refuge data shows that there are very limited side effects. The superiority of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer side stuff than chemotherapy, which is the only other treatment option for these patients. In addition, Provenge has improved survival over chemotherapy.
The mean survival time for men given Provenge is 4,5 months, although some patients saw their lives extended by two to three years. "This is a newly nearby treatment, with very limited standpoint effects, compared to anything else that a man would be considering in this state". Hall was to present the results on Monday at the American Urological Association annual convergence in San Francisco.
Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved nobility of viability and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do appear as activities without any restrictions, the researchers noted.
Tuesday 26 November 2019
Slowly Progressive Prostate Cancer Need To Be Watched Instead Of Treatment
Slowly Progressive Prostate Cancer Need To Be Watched Instead Of Treatment.
For patients with prostate cancer that has a bawdy imperil of progression, effectual surveillance, also known as "watchful waiting," may be a suitable treatment option, according to a large-scale study from Sweden. The publication of how (or whether) to treat localized prostate cancer is controversial because, especially for older men, the tumor may not ripen far enough to cause real trouble during their remaining expected lifespan. In those cases, deferring care until there are signs of disease progression may be the better option.
The researchers looked at almost 6900 patients from the National Prostate Cancer Registry Sweden, period 70 or younger, who had localized prostate cancer and a dejected or intermediate risk that the cancer would progress. From 1997 through December 2002, over 2000 patients were assigned to animated surveillance, close to 3400 underwent thorough prostatectomy (removal of the prostate and some surrounding tissue), and more than 1400 received radiation therapy.
For patients with prostate cancer that has a bawdy imperil of progression, effectual surveillance, also known as "watchful waiting," may be a suitable treatment option, according to a large-scale study from Sweden. The publication of how (or whether) to treat localized prostate cancer is controversial because, especially for older men, the tumor may not ripen far enough to cause real trouble during their remaining expected lifespan. In those cases, deferring care until there are signs of disease progression may be the better option.
The researchers looked at almost 6900 patients from the National Prostate Cancer Registry Sweden, period 70 or younger, who had localized prostate cancer and a dejected or intermediate risk that the cancer would progress. From 1997 through December 2002, over 2000 patients were assigned to animated surveillance, close to 3400 underwent thorough prostatectomy (removal of the prostate and some surrounding tissue), and more than 1400 received radiation therapy.
Thursday 22 March 2018
New Blood Test Can Detect Prostate Cancer More Accurately And Earlier
New Blood Test Can Detect Prostate Cancer More Accurately And Earlier.
A untrodden blood check-up to spot a cluster of specific proteins may point out the presence of prostate cancer more accurately and earlier than is now possible, new research suggests. The test, which has thus far only been assessed in a captain study, is 90 percent accurate and returned fewer false-positive results than the prostate definitive antigen (PSA) test, which is the current clinical standard, the researchers added. Representatives of the British companionship that developed the test, Oxford Gene Technology in Oxford, presented the findings Tuesday at the International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Denver, hosted by the American Association for Cancer Research.
The analysis looks for auto-antibodies for cancer, like to the auto-antibodies associated with autoimmune diseases such as font 1 diabetes, rheumatoid arthritis and lupus. "These are antibodies against our own proteins," explained John Anson, Oxford's defect president of biomarker discovery. "We're demanding to look for antibodies generated in the original stages of cancer. This is an exquisitely sensitive mechanism that we're exploring with this technology".
Such a investigation generates some excitement not only because it could theoretically detect tumors earlier, when they are more treatable, but auto-antibodies can be "easily detected in blood serum. It's not an invasive technique. It's a open blood test". The researchers came up with groups of up to 15 biomarkers that were backsheesh in prostate cancer samples and not present in men without prostate cancer. The assay also was able to differentiate actual prostate cancer from a more benign condition.
Because a unequivocal is currently pending, Anson would not list the proteins included in the test. "We are accepted on to a much more exhaustive follow-on study. At the moment, we are taking over 1,800 samples, which includes 1,200 controls with a full range of 'interfering diseases' that men of 50-plus are prone to and are running a very large analytical validation study".
A untrodden blood check-up to spot a cluster of specific proteins may point out the presence of prostate cancer more accurately and earlier than is now possible, new research suggests. The test, which has thus far only been assessed in a captain study, is 90 percent accurate and returned fewer false-positive results than the prostate definitive antigen (PSA) test, which is the current clinical standard, the researchers added. Representatives of the British companionship that developed the test, Oxford Gene Technology in Oxford, presented the findings Tuesday at the International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Denver, hosted by the American Association for Cancer Research.
The analysis looks for auto-antibodies for cancer, like to the auto-antibodies associated with autoimmune diseases such as font 1 diabetes, rheumatoid arthritis and lupus. "These are antibodies against our own proteins," explained John Anson, Oxford's defect president of biomarker discovery. "We're demanding to look for antibodies generated in the original stages of cancer. This is an exquisitely sensitive mechanism that we're exploring with this technology".
Such a investigation generates some excitement not only because it could theoretically detect tumors earlier, when they are more treatable, but auto-antibodies can be "easily detected in blood serum. It's not an invasive technique. It's a open blood test". The researchers came up with groups of up to 15 biomarkers that were backsheesh in prostate cancer samples and not present in men without prostate cancer. The assay also was able to differentiate actual prostate cancer from a more benign condition.
Because a unequivocal is currently pending, Anson would not list the proteins included in the test. "We are accepted on to a much more exhaustive follow-on study. At the moment, we are taking over 1,800 samples, which includes 1,200 controls with a full range of 'interfering diseases' that men of 50-plus are prone to and are running a very large analytical validation study".
Monday 12 March 2018
New Ways Of Treating Prostate Cancer And Ovarian Cancer
New Ways Of Treating Prostate Cancer And Ovarian Cancer.
New probe supports unconventional ways to treat ovarian and prostate cancer, while producing a dejection for those with a certain form of colon cancer. Both the ovarian and prostate cancer trials could replace clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the disease in its advanced stages and more men getting shedding therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual intersection in Chicago. A third trial, looking at the effectiveness of cetuximab (Erbitux) in treating sure colon cancer patients, found the numb made little difference to their survival.
The first study found that adding Avastin to average chemotherapy (carboplatin and paclitaxel) and continuing with "maintenance" Avastin after chemo absolutely slowed the time-to-disease recurrence in women with advanced ovarian cancer. Avastin is an anti-angiogenic drug, drift it interferes with a tumor's blood supply. "This is the first molecular-targeted and first anti-angiogenesis treatment to demonstrate benefit in this population and, combined with chemotherapy followed by Avastin maintenance, should be considered as one typical option for women with this disease," said lead researcher Dr Robert A Burger, overseer of the Women's Cancer Center at Fox Chase Cancer Center in Philadelphia.
So "This is a untrained potential treatment paradigm for stage 3 and 4 ovarian cancer," added Dr Jennifer Obel, an attending doctor at Northshore University Health System and chairlady of a Sunday news conference at which these results were presented. The phase 3 con involved almost 1,900 women with stage 3 and stage 4 ovarian cancer. Those who received timber chemotherapy plus Avastin, and then maintenance Avastin, for up to 10 months lived just over 14 months without their contagion progressing compared with about 10 months for those receiving standard chemotherapy alone.
Those who received chemo extra Avastin but no maintenance drug lived without a recurrence for 11,3 months, a diversity not considered statistically significant. "I'm cautiously optimistic about this data. It without doubt shows that those who had maintenance Avastin had improved profession-free survival," said Dr Robert Morgan, co-director of the gynecologic oncology program at City of Hope Cancer Center in Duarte, Calif. "I dream we have to hold on for longer term outcomes before we make definite conclusions. It's too beforehand for overall survival benefit data".
However, he pointed out, a four-month difference for progression-free survival is "substantial". Doctors are already using Avastin off-label universally to treat ovarian cancer although it is not yet approved for this use. It has been shown to be more dynamic in this cancer than in many cancers for which it is approved.
New probe supports unconventional ways to treat ovarian and prostate cancer, while producing a dejection for those with a certain form of colon cancer. Both the ovarian and prostate cancer trials could replace clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the disease in its advanced stages and more men getting shedding therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual intersection in Chicago. A third trial, looking at the effectiveness of cetuximab (Erbitux) in treating sure colon cancer patients, found the numb made little difference to their survival.
The first study found that adding Avastin to average chemotherapy (carboplatin and paclitaxel) and continuing with "maintenance" Avastin after chemo absolutely slowed the time-to-disease recurrence in women with advanced ovarian cancer. Avastin is an anti-angiogenic drug, drift it interferes with a tumor's blood supply. "This is the first molecular-targeted and first anti-angiogenesis treatment to demonstrate benefit in this population and, combined with chemotherapy followed by Avastin maintenance, should be considered as one typical option for women with this disease," said lead researcher Dr Robert A Burger, overseer of the Women's Cancer Center at Fox Chase Cancer Center in Philadelphia.
So "This is a untrained potential treatment paradigm for stage 3 and 4 ovarian cancer," added Dr Jennifer Obel, an attending doctor at Northshore University Health System and chairlady of a Sunday news conference at which these results were presented. The phase 3 con involved almost 1,900 women with stage 3 and stage 4 ovarian cancer. Those who received timber chemotherapy plus Avastin, and then maintenance Avastin, for up to 10 months lived just over 14 months without their contagion progressing compared with about 10 months for those receiving standard chemotherapy alone.
Those who received chemo extra Avastin but no maintenance drug lived without a recurrence for 11,3 months, a diversity not considered statistically significant. "I'm cautiously optimistic about this data. It without doubt shows that those who had maintenance Avastin had improved profession-free survival," said Dr Robert Morgan, co-director of the gynecologic oncology program at City of Hope Cancer Center in Duarte, Calif. "I dream we have to hold on for longer term outcomes before we make definite conclusions. It's too beforehand for overall survival benefit data".
However, he pointed out, a four-month difference for progression-free survival is "substantial". Doctors are already using Avastin off-label universally to treat ovarian cancer although it is not yet approved for this use. It has been shown to be more dynamic in this cancer than in many cancers for which it is approved.
Thursday 5 October 2017
Statins May Reduce The Risk Of Prostate Cancer
Statins May Reduce The Risk Of Prostate Cancer.
Cholesterol-lowering statins significantly mark down prostate tumor inflammation, which may hand lower the risk of disease progression, redesigned study findings suggest. Duke University Medical Center researchers found that the use of statins before prostate cancer surgery was associated with a 69 percent reduced good chance of inflammation preferential prostate tumors.
For the study, the researchers examined tissue samples of prostate tumors from 236 men undergoing prostate cancer surgery. The patients included 37 who took statins during the year erstwhile to their surgery.
Overall, 82 percent of the men had riotous cells in their prostate tumors and about one-third had signal tumor inflammation. After they accounted for factors such as age, mill-race and body-mass index (a measurement that is based on weight and height), the Duke team concluded that statin use was associated with reduced swelling within tumors.
Cholesterol-lowering statins significantly mark down prostate tumor inflammation, which may hand lower the risk of disease progression, redesigned study findings suggest. Duke University Medical Center researchers found that the use of statins before prostate cancer surgery was associated with a 69 percent reduced good chance of inflammation preferential prostate tumors.
For the study, the researchers examined tissue samples of prostate tumors from 236 men undergoing prostate cancer surgery. The patients included 37 who took statins during the year erstwhile to their surgery.
Overall, 82 percent of the men had riotous cells in their prostate tumors and about one-third had signal tumor inflammation. After they accounted for factors such as age, mill-race and body-mass index (a measurement that is based on weight and height), the Duke team concluded that statin use was associated with reduced swelling within tumors.
Thursday 19 January 2017
Smoking And Excess Weight Can Lead To A Cancer
Smoking And Excess Weight Can Lead To A Cancer.
Men with prostate cancer may raise their survival chances if they change animal fats and carbohydrates in their slim with healthy fats such as olive oils, nuts and avocados, new research suggests June 2013. Men who substituted 10 percent of their circadian calories from animal fats and carbs with such sturdy fats as olive oil, canola oil, nuts, seeds and avocados were 29 percent less qualified to die from spreading prostate cancer and 26 percent less disposed to to die from any other disease when compared to men who did not make this healthy swap, the study found. And a not any bit seems to go a long way.
Specifically, adding just one daily tablespoon of an oil-based salad dressing resulted in a 29 percent mark down risk of dying from prostate cancer and a 13 percent take down risk of dying from any other cause, the study contended. In the study, nearly 4600 men who had localized or non-spreading prostate cancer were followed for more than eight years, on average. During the study, 1064 men died.
Of these, 31 percent died from kindness disease, somewhat more than 21 percent died as a sequel of prostate cancer and slightly less than 21 percent died as a effect of another type of cancer. The findings appeared online June 10 in JAMA Internal Medicine. The go into can't say for sure that including healthy fats in the reduce was responsible for the survival edge seen among men.
Men with prostate cancer may raise their survival chances if they change animal fats and carbohydrates in their slim with healthy fats such as olive oils, nuts and avocados, new research suggests June 2013. Men who substituted 10 percent of their circadian calories from animal fats and carbs with such sturdy fats as olive oil, canola oil, nuts, seeds and avocados were 29 percent less qualified to die from spreading prostate cancer and 26 percent less disposed to to die from any other disease when compared to men who did not make this healthy swap, the study found. And a not any bit seems to go a long way.
Specifically, adding just one daily tablespoon of an oil-based salad dressing resulted in a 29 percent mark down risk of dying from prostate cancer and a 13 percent take down risk of dying from any other cause, the study contended. In the study, nearly 4600 men who had localized or non-spreading prostate cancer were followed for more than eight years, on average. During the study, 1064 men died.
Of these, 31 percent died from kindness disease, somewhat more than 21 percent died as a sequel of prostate cancer and slightly less than 21 percent died as a effect of another type of cancer. The findings appeared online June 10 in JAMA Internal Medicine. The go into can't say for sure that including healthy fats in the reduce was responsible for the survival edge seen among men.
Saturday 23 November 2013
Mass Screening For Prostate Cancer Can Have Unpleasant Consequences
Mass Screening For Prostate Cancer Can Have Unpleasant Consequences.
Health campaigns that highlight the mind-boggler of destitute screening rates for prostate cancer to sanction such screenings seem to have an unintended effect: They discourage men from undergoing a prostate exam, a rejuvenated German study suggests. The finding, reported in the current issue of Psychological Science, stems from ply by a research team from the University of Heidelberg that gauged the intention to get screened for prostate cancer amidst men over the age of 45 who reside in two German cities.
In earlier research, the reflect on authors had found that men who had never had such screenings tended to believe that most men hadn't either. In the prevalent effort, the team exposed men who had never been screened to one of two health facts statements: either that only 18 percent of German men had been screened in the past year, or that 65 percent of men had been screened.
Health campaigns that highlight the mind-boggler of destitute screening rates for prostate cancer to sanction such screenings seem to have an unintended effect: They discourage men from undergoing a prostate exam, a rejuvenated German study suggests. The finding, reported in the current issue of Psychological Science, stems from ply by a research team from the University of Heidelberg that gauged the intention to get screened for prostate cancer amidst men over the age of 45 who reside in two German cities.
In earlier research, the reflect on authors had found that men who had never had such screenings tended to believe that most men hadn't either. In the prevalent effort, the team exposed men who had never been screened to one of two health facts statements: either that only 18 percent of German men had been screened in the past year, or that 65 percent of men had been screened.
Subscribe to:
Posts (Atom)